Royalty Pharma, a firm pecializing in acquiring pharmaceutical royalties, completed the acquisition of a 43% of Roche's Risdiplam royalties, an investigational, orally administered survival motor neuron-2 (SMN2) splicing modifier for the treatment of spinal muscular atrophy (SMA), from PTC Therapeutics, a provider of biopharmaceutical products, for $650m. “The discovery, development and expected commercialization of risdiplam exemplifies how PTC’s strengths in novel scientific approaches to diseases with high unmet needs can generate value for the benefit of all of our stakeholders. Today’s announcement of our strategic partnership with Royalty Pharma brings forward significant, non-dilutive capital to drive further innovation and growth across our robust and diverse rare disorder portfolio," Stuart W. Peltz, PTC Therapeutics Chief Executive Officer.